@article{ATM29076,
author = {Ning Hu and Zhiheng Cheng and Yifan Pang and Hongmian Zhao and Hui Ding and Li Chen and Qianyu Li and Yu Han and Tong Qin and Yifeng Dai and Yijie Zhang and Jinlong Shi and Depei Wu and Lin Fu},
title = {Prognostic effect of allogeneic hematopoietic stem cell transplantation on first and non-first complete remission in acute myeloid leukemia},
journal = {Annals of Translational Medicine},
volume = {7},
number = {18},
year = {2019},
keywords = {},
abstract = {Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered the cure for intermediate or adverse-risk acute myeloid leukemia (AML) (1). It offers patients longer overall survival (OS) (2-4). Unfortunately, human leukocyte antigen (HLA) matched related donor is unavailable in more than 70% patients. Some of these patients, may experience relapse and subsequently achieve CR (non-CR1) with treatment. Some non-CR1 patients eventually receive allo-HSCT. It is unclear whether allo-HSCT will improve the survival of these patients.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/29076}
}